Asset profile
Cerebrolysin
Peptide
Evidence outlook · lead readout
NCT00911807 · Alzheimer Disease
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT00911807: This was a randomized, quadruple-blinded, three-arm trial with 217 patients, comparing Cerebrolysin plus donepezil, Cerebrolysin alone, and donepezil alone. The primary endpoint, change in ADAS-Cog+ at week 28, did not show a statistically significant difference among the groups (overall p=0.6348; pairwise comparisons all non-significant), so the study did not meet its primary cognitive endpoint. Although the design was strong, the null primary result limits the evidence to a moderate level.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 2 direct rivals (same mechanism and indication), 3 same-class, 60 same-indication; 6 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cerebrolysin: this drug | Phase 3 | Peptide | Multi-target (ginsenoside) | ||
| MLC901 (NeuroAiD II) | Phase 3 | Botanical | Multi-target (ginsenoside) | ||
| PM012 | Phase 2/3 | Botanical | Multi-target (ginsenoside) | ||
| Shenfu Injection (Shenfu Zhusheye) | Phase 2/3 | Botanical | Multi-target (ginsenoside) | ||
| Jia Shen Tablet | Phase 2 | Botanical | Multi-target (ginsenoside) | ||
| QiShenYiQi | Phase 2 | Botanical | Multi-target (ginsenoside) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 | ||
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | ||
| Blarcamesine | Phase 3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
January 2027 (1)
What to watch
July 2027 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.